Ottawa Hospital Research Institute
Clinical Trials
529
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (402 trials with phase data)• Click on a phase to view related trials
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
- Conditions
- Bronchopulmonary Dysplasia (BPD)ELGAN (22-28SA)
- Interventions
- Biological: Human Allogenic Umbilical Cord Mesenchymal Stromal CellsOther: Sham procedure control
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 168
- Registration Number
- NCT07058025
- Locations
- 🇨🇦
Royal Alexandra Hospital/Stollery Children's Hospital, Edmonton, Alberta, Canada
🇨🇦McMaster Children's Hospital, Hamilton, Ontario, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Lower Trapezius Tendon Transfer vs Partial Cuff Repair in Massive Rotator Cuff Tears
- Conditions
- Massive Rotator Cuff Tear
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT07051889
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Variability and Post-op AEs: Does Preoperative CardioPulmonary Variability Assessment Identify Risk of Postoperative Adverse Events Following Thoracic Surgery
- Conditions
- Thoracic CancerComplication,Postoperative
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 130
- Registration Number
- NCT07016022
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
- Conditions
- Granulomatosis With PolyangiitisMicroscopic Polyangiitis (MPA)
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 36
- Registration Number
- NCT06983821
- Locations
- 🇨🇦
St-Joseph's Hospital, Hamilton, Ontario, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
- Conditions
- SVTThrombosisSuperficial Vein Thrombosis
- Interventions
- Drug: Full dose rivaroxabanDrug: Low dose rivaroxaban and placebo
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT06965998
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦Hopital Montfort, Ottawa, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 105
- Next
News
Tranexamic Acid Fails to Reduce Transfusions in Radical Cystectomy: TACT Trial
• A randomized, double-blind, placebo-controlled trial (TACT) assessed tranexamic acid (TXA) in patients undergoing radical cystectomy for bladder cancer. • The study found that TXA did not significantly reduce the need for red blood cell transfusions within 30 days post-surgery compared to placebo. • Secondary outcomes, including blood loss and thromboembolic events, also showed no significant differences between the TXA and placebo groups. • The findings suggest that routine use of TXA during open radical cystectomy for bladder cancer is not recommended.